NEUMARQProject ID: 662975
Finanziato nell'ambito di:
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
Neurodegenerative disease biomarkers based on high quality wireless EEG.
Dettagli del progetto
Costo totale:EUR 71 429
Contributo UE:EUR 50 000
Argomento (i):PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Invito a presentare proposte:H2020-SMEINST-1-2014See other projects for this call
Meccanismo di finanziamento:SME-1 - SME instrument phase 1
The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care.
Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care.
Contributo UE: EUR 50 000
AVENIDA TIBIDABO 47 BIS